Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Roivant Sciences Ltd. (Nasdaq: ROIV) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Bermuda-incorporated biopharmaceutical issuer with common shares listed on The Nasdaq Global Select Market, Roivant files annual reports, quarterly updates, current reports on Form 8-K, proxy statements and other disclosures that describe its business, governance, financial condition and material events.
Through Roivant’s filings, investors can review detailed information on its biopharmaceutical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as the activities of subsidiaries such as Priovant Therapeutics, Immunovant, Pulmovant and Genevant. Current reports on Form 8-K have been used to furnish press releases on quarterly financial results, to report positive Phase 3 VALOR data in dermatomyositis, to provide updates on Graves’ disease development at Immunovant, and to disclose authorization of common share repurchase programs.
Roivant’s periodic reports discuss consolidated research and development and general and administrative expenses, share-based compensation, gains and losses from transactions such as the sale of Telavant net assets and the sale of its equity interest in Dermavant, and income or loss from discontinued operations. The company’s definitive proxy statement on Schedule 14A describes its annual general meeting of shareholders, director elections, auditor ratification and advisory votes on executive compensation, and lays out governance and compensation policies.
On Stock Titan, Roivant filings are paired with AI-powered summaries designed to help readers interpret complex documents. Users can quickly see the key points from 10-K and 10-Q reports, understand the significance of 8-K disclosures, and locate information related to capital allocation, clinical programs and subsidiary activities. Form 4 and other ownership-related filings, when available, can be used to track insider transactions and equity incentives disclosed by the company.
Frank M. Torti filed a Form 144 disclosing an intended sale of 1,600,000 shares of common stock of the issuer ROIV on 02/20/2026 tied to an exercise of stock options. The filing shows an aggregate value of $44,032,000 and identifies Morgan Stanley Smith Barney LLC as broker.
The filing also records prior 10b5-1 sales by Mr. Torti of 1,400,000 shares on 02/19/2026 with proceeds of $38,392,834.26. Transaction mechanics are shown as cash proceeds from option exercise.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported exercising stock options and selling shares on the same day. He exercised options for 200,000 Common Shares at an exercise price of $3.85 per share, then sold 200,000 Common Shares in open-market transactions at a weighted average price of $26.49 per share, with individual sale prices ranging from $26.35 to $26.69. Following these transactions, he directly owned 1,654,597 Common Shares and held 5,044,834 stock options.
Roivant Sciences Ltd. received an amended ownership report from SoftBank-affiliated entities. The filing shows that SB Investment Advisers (UK) Limited, SoftBank Vision Fund L.P., SVF Holdings (UK) LLP and SVF Investments (UK) Limited together beneficially own 16,413,603 common shares, representing 2.3% of Roivant’s outstanding stock.
SVF Investments (UK) Limited is the record holder of these shares, and the other SoftBank entities may be deemed to share voting and investment power through their control structure. The ownership is calculated based on 715,701,137 common shares outstanding as of February 2, 2026 and is now reported as 5% or less of the class.
Roivant Sciences director-associated entity reports share sales. An investment entity, QVT Financial Investment Cayman Ltd., which is associated with director Keith S. Manchester, executed several indirect open-market sales of Roivant Sciences common shares between February 11 and 13, 2026.
Transactions included sales of 425,000 shares at $26.67, 150,000 shares at $26.72, 275,000 shares at $26.76, 150,784 shares at $26.49, and 225,000 shares at $26.50. Following these trades, QVT Financial Investment Cayman Ltd. is reported as indirectly holding 15,127,329 common shares.
The filing notes that Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
Roivant Sciences Ltd. reported insider share sales linked to director Daniel Allen Gold. QVT Financial Investment Cayman Ltd., where Gold is one of three directors, executed a series of open-market sales of Roivant common shares on February 11–13, 2026 at prices between $26.49 and $26.76 per share.
Individual transactions ranged from 150,000 to 425,000 common shares, with the last reported sale at $26.50 per share. Following the final transaction, 15,127,329 common shares were indirectly held by QVT Financial Investment Cayman Ltd. Gold shares voting and investment control over these shares and disclaims beneficial ownership beyond his pecuniary interest.
QVT Financial LP, acting as a director by deputization of Roivant Sciences Ltd., reported a series of indirect open‑market sales of Roivant common shares held by QVT Financial Investment Cayman Ltd. on February 11–13, 2026. The transactions included sales of 425,000, 150,000, 275,000, 150,784 and 225,000 common shares at prices between $26.49 and $26.76 per share. Following these trades, QVT Financial Investment Cayman Ltd. held 15,127,329 Roivant common shares indirectly for QVT Financial LP, while footnotes state that QVT Financial LP may be deemed to beneficially own 25,161,237 common shares across several related entities.
Roivant Sciences Ltd. insider Eric Venker has filed a notice to sell 200,000 common shares under Rule 144. The shares are to be sold through Rockefeller Financial LLC on the NASDAQ, with an aggregate market value of about $5.3 million, versus 715,701,137 shares outstanding.
The 200,000 shares were acquired on 02/13/2026 by exercising options originally granted on 04/20/2022, with payment made by wire. Over the past three months, Venker has already sold several blocks of Roivant common shares, including 200,000 shares on 12/09/2025 for $4,169,131.30 and 200,000 shares on 01/12/2026 for $4,383,694.07.
Vivek Ramaswamy reported a 6.8% beneficial ownership stake in Roivant Sciences Ltd. common shares as of the event dated 12/31/2025. He is deemed to beneficially own 48,428,792 common shares, made up of 33,709,547 restricted share awards and 14,719,245 common shares underlying options.
The ownership percentage is calculated using 710,210,860 common shares, based on 695,491,615 shares outstanding as of November 3, 2025 and options expected to vest and settle within 60 days of December 31, 2025. The reported holdings exclude 13,357,857 shares held solely by his spouse.
Sukhatme Mayukh reported multiple insider transaction types in a Form 4 filing for ROIV. The filing lists transactions totaling 1,954,674 shares at a weighted average price of $19.58 per share. Following the reported transactions, holdings were 19,488,105 shares.